OTCMKTS:IMUN Immune Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immune Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.02 0.00 (0.00 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$0.02Now: $0.02▼$0.0250-Day Range$0.01MA: $0.02▼$0.0252-Week Range$0.00Now: $0.02▼$0.05Volume348,735 shsAverage Volume1.44 million shsMarket Capitalization$7,476.00P/E RatioN/ADividend YieldN/ABeta0.66 ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Immune Therapeutics, Inc., together with its subsidiaries, focuses on the development and commercialization of therapeutic treatments for cancer, human immunodeficiency virus (HIV)/AIDS, and autoimmune and immune disorders in the United States and internationally. It develops methionine enkephalin IRT-101, a small synthetic pentapeptide; and low-dose naltrexone IRT-103, an opioid receptor antagonist that stimulates and/or regulates the immune system to treat a range of autoimmune diseases, including multiple sclerosis; immune disorders, such as Crohn's disease and cancer; and viral infections comprising HIV/AIDS. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in December 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Immune Therapeutics. Previous Next 2.9 Community Rank Outperform VotesImmune Therapeutics has received 50 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmune Therapeutics has received 37 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmune Therapeutics has received 57.47% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Immune Therapeutics and other stocks. Vote “Outperform” if you believe IMUN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMUN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmune Therapeutics does not currently pay a dividend.Dividend GrowthImmune Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immune Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.70% of the stock of Immune Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 13.30% of the stock of Immune Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.58 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:IMUN Previous Symbol CUSIPN/A CIK1559356 Webwww.immunetherapeutics.com Phone888-613-8802Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$110,000.00 Price / Sales0.07 Cash FlowN/A Price / Cash FlowN/A Book Value($30.76) per share Price / Book0.00Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-3,400,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-20,660.61%Miscellaneous Employees4 Outstanding Shares445,000Market Cap$7,476.00 Next Earnings Date11/17/2020 (Estimated) OptionableNot Optionable $0.02 0.00 (0.00 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IMUN News and Ratings via Email Sign-up to receive the latest news and ratings for IMUN and its competitors with MarketBeat's FREE daily newsletter. Immune Therapeutics (OTCMKTS:IMUN) Frequently Asked Questions How has Immune Therapeutics' stock price been impacted by COVID-19? Immune Therapeutics' stock was trading at $0.0064 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IMUN stock has increased by 162.5% and is now trading at $0.0168. View which stocks have been most impacted by COVID-19. When is Immune Therapeutics' next earnings date? Immune Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 17th 2020. View our earnings forecast for Immune Therapeutics. How were Immune Therapeutics' earnings last quarter? Immune Therapeutics Inc (OTCMKTS:IMUN) issued its earnings results on Friday, August, 14th. The company reported ($1.76) earnings per share (EPS) for the quarter. View Immune Therapeutics' earnings history. Are investors shorting Immune Therapeutics? Immune Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 22,500 shares, an increase of 58.5% from the August 31st total of 14,200 shares. Based on an average daily volume of 355,100 shares, the days-to-cover ratio is currently 0.1 days. View Immune Therapeutics' Short Interest. Who are some of Immune Therapeutics' key competitors? Some companies that are related to Immune Therapeutics include Acusphere (ACUS), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aoxing Pharmaceutical (AOXG), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG), China Health Industries (CHHE), Diadexus (DDXSQ) and Epirus Biopharmaceuticals (EPRSQ). View all competitors. What other stocks do shareholders of Immune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Therapeutics investors own include Northwest Biotherapeutics (NWBO), Arch Therapeutics (ARTH), Amerigo Resources (ARREF), Blue Apron (APRN), Africa Oil (AOIFF), Amarin (AMRN), AK Steel (AKS), Asanko Gold (AKG), Argitek (AGTK) and Agenus (AGEN). Who are Immune Therapeutics' key executives? Immune Therapeutics' management team includes the following people: Ms. Noreen Griffin, Founder, CEO, Pres & Director (Age 66)Mr. Peter Aronstam, Chief Financial Officer (Age 67)Dr. Fengping Shan, Chief Science Officer (Age 60)Dr. Angus George Dalgleish, Chief Medical Officer and Director of R&D (Age 69)Dr. Joseph M. Fortunak, VP of Global R&D and Chemical Devel. (Age 64) What is Immune Therapeutics' stock symbol? Immune Therapeutics trades on the OTCMKTS under the ticker symbol "IMUN." How do I buy shares of Immune Therapeutics? Shares of IMUN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Immune Therapeutics' stock price today? One share of IMUN stock can currently be purchased for approximately $0.02. How big of a company is Immune Therapeutics? Immune Therapeutics has a market capitalization of $7,476.00 and generates $110,000.00 in revenue each year. Immune Therapeutics employs 4 workers across the globe. What is Immune Therapeutics' official website? The official website for Immune Therapeutics is www.immunetherapeutics.com. How can I contact Immune Therapeutics? Immune Therapeutics' mailing address is 37 NORTH ORANGE AVENUE SUITE 800M, WINTER PARK FL, 32792. The company can be reached via phone at 888-613-8802. This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
